Parnax Lab Limited

BSE: 506128
Parnax Lab Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L36912MH1982PLC027925 Incorporated 03 August 1982 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 506128 Public Limited Company pharma
Data last updated
Market Cap
₹130 Cr
PARNAXLAB · NSE
Share Price
₹113.14
+1.26% today
Revenue
₹249 Cr
FY 2025-26 · +38.3% YoY
EBITDA
₹25.88 Cr
Margin 10.4%
Net Profit
₹12.80 Cr
FY 2025-26 · +9.3% YoY
P/E (TTM)
12.8x
P/B 1.4x

About Parnax Lab Limited

Data last updated:

Parnax Lab Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 August 1982 and has been in existence for over 44 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L36912MH1982PLC027925. Its GSTIN is 27AAACK1457E1ZT (Maharashtra). The company holds 3 GST registrations, of which 2 are active. Its shares are listed on BSE: 506128.

The company has an authorised share capital of ₹13 Cr and a paid-up capital of ₹11.49 Cr. It was formerly known as Krishna-Deep Trade and Investment Ltd. It is led by directors including Mihir Prakash Shah (Managing Director) and Ami Mihir Shah.

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Gala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹248.54 Cr, a growth of 32.39% compared to the previous year. The net worth stands at ₹95.14 Cr (up 14.49% YoY). Total assets are valued at ₹179.22 Cr (up 16.83% YoY).

Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Naxpar Group. As per MCA filings, the company has open charges of ₹24.2 Cr and satisfied charges of ₹4.66 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naxparlab.com.

Company Details of Parnax Lab Limited
CIN L36912MH1982PLC027925
Registration Number 027925
Incorporation Date 03 August 1982
ROC Mumbai
Listing Status Listed (BSE: 506128)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Mihir Prakash Shah Managing Director Ami Mihir Shah Director Yogesh Kantilal Varia Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    naxparlab.com
  • Social Media
    Locked
  • Registered Address
    Gala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Parnax Lab Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Parnax Lab Limited report

Financials, compliance, directors, charges, ownership and filings for Parnax Lab Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Parnax Lab

Parnax Lab has one previous CIN (Corporate Identification Number): L67120MH1982PLC027925. The current CIN is L36912MH1982PLC027925, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L36912MH1982PLC027925Current
L67120MH1982PLC027925Previous

Associated Brands with Parnax Lab

Parnax Lab operates one associated brand: Naxpar Group. Each brand links to its own profile.

BrandDescriptionWebsite
Naxpar Group
Pharmaceutical, cosmetic, herbal, and nutraceutical formulations are manufactured.naxparlab.com

Business Activity of Parnax Lab

The main business activity of Parnax Lab is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details for Parnax Lab Limited

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Parnax Lab

Parnax Lab Limited is audited by M/s. C.N.Patel & Co for the financial year 2022.

NameStatusAppointment DateCessation Date
M/s. C.N.Patel & CoLockedLockedLocked
Premium access

Complete auditor history for Parnax Lab Limited

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Parnax Lab Limited

Parnax Lab has 6 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ami Mihir Shah
Also directs: Naxpar Medicamentos LLP, Naxpar Health Concepts Private Limited, Naxpar Int LLP
Director31 Mar 201511 Years 6 MonthsCurrent
Yogesh Kantilal Varia
Also directs: Naxpar Pharma Private Limited
Director28 May 20215 Years 4 MonthsCurrent
Vijaykumar Shivaji Ayare
Also directs: Wanbury Pharma Limited
Director10 Feb 20251 Years 7 MonthsCurrent
Mihir Prakash Shah
Also directs: Novomed Pharma Pvt. Ltd, Naxpar Pharma Private Limited
Managing Director05 Jul 20242 Years 2 MonthsCurrent
Binoy Baiju Shah
Also directs: Novomed Pharma Pvt. Ltd, Naxpar Medicamentos LLP, Naxpar Health Concepts Private Limited
Director05 Jul 20242 Years 2 MonthsCurrent
Harish Sunderlal Panpalia
Also directs: Naxpar Pharma Private Limited
Director11 Aug 20233 Years 1 MonthsCurrent
View all directors

Financials of Parnax Lab Limited FY 2025-26 filings available

Parnax Lab Limited reported revenue of ₹248.54 Cr (up 32.39% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹249 Cr
+32.4% YoY
EBITDA
₹25.88 Cr
-3.3% YoY
Profit After Tax
₹12.80 Cr
+9.3% YoY
Net Worth
₹95.14 Cr
+14.5% YoY
Total Assets
₹179 Cr
+16.8% YoY
Total Debt
₹82.79 Cr
+19.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24918818916816390.0695.31
Revenue growth+38.3%-2.5%+14.2%+3.3%+74.7%-9.9%-9.8%
EBITDA25.8826.7723.5522.9923.039.946.43
EBITDA margin+10.4%+14.3%+12.5%+13.7%+14.1%+11.0%+6.8%
Profit before tax15.9015.6812.0612.2812.26(0.09)(1.97)
Net profit12.8011.719.608.618.23(0.38)(2.92)
Net profit margin+5.2%+6.2%+5.1%+5.1%+5.1%-0.4%-3.1%
EPS (₹)10.2710.038.377.508.40(0.43)(3.43)
Balance sheet
Total assets17915315311711891.7884.37
Net worth95.1483.1071.5862.1648.1832.5432.79
Total debt82.7969.5380.6454.7269.0858.9051.23
Cash & bank2.262.681.882.785.781.271.30
Net working capital48.2033.7240.6933.6638.5626.6324.51
Cash flow
Cash from operations8.0032.3015.8820.918.556.318.75
Cash from investing(16.39)(16.39)(31.52)(9.92)(16.50)(6.56)(13.33)
Cash from financing8.18(15.82)14.82(14.07)12.130.055.03
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue56.8069.6362.9462.6053.3849.0440.2248.36
Revenue growth (YoY)+6.4%+42.0%+56.5%+29.5%+6.5%+5.8%-21.1%+13.5%
Other income0.151.990.970.630.180.430.190.95
EBITDA4.304.665.718.087.446.634.287.24
EBITDA margin+7.6%+6.7%+9.1%+12.9%+13.9%+13.5%+10.6%+15.0%
Depreciation2.222.041.962.101.941.831.791.94
Interest1.641.611.471.401.221.281.231.38
Profit before tax0.593.003.255.214.463.951.454.87
Tax0.170.810.541.581.181.030.241.45
Net profit0.422.192.713.633.282.921.213.42
EPS (₹)0.371.902.373.152.852.551.062.97
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6.637.027.447.477.152.377.68
Revenue growth+42.7%+8.0%-9.5%+2.3%+105.0%-60.5%+11.6%
EBITDA(1.62)1.242.091.561.37(0.45)0.55
EBITDA margin-24.4%+17.7%+28.1%+20.9%+19.2%-19.0%+7.2%
Profit before tax0.661.872.431.610.78(1.25)(0.45)
Net profit0.931.411.811.190.54(1.13)(1.99)
Net profit margin+14.0%+20.1%+24.3%+15.9%+7.6%-47.7%-25.9%
EPS (₹)0.771.211.591.050.55(1.33)(2.36)
Balance sheet
Total assets23.4522.5721.1820.4421.9516.1416.90
Net worth23.4222.5521.1619.3612.754.715.82
Total debt0.000.000.001.079.2011.4111.06
Cash & bank1.101.280.461.284.350.110.12
Net working capital10.838.966.965.576.584.185.18
Cash flow
Cash from operations(0.72)0.280.08(0.28)(0.36)0.472.20
Cash from investing0.57(0.19)0.300.140.000.00(0.01)
Cash from financing(0.03)(0.02)(1.21)(2.92)4.59(0.48)(1.55)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2.570.252.711.701.970.840.991.54
Revenue growth (YoY)+30.5%-70.2%+173.7%+10.4%-46.2%-50.9%-64.3%-15.9%
Other income0.211.760.220.200.190.190.170.18
Total expenses1.913.271.961.201.811.120.921.34
EBITDA0.66(3.02)0.750.500.16(0.28)0.070.20
EBITDA margin+25.7%-1208.0%+27.7%+29.4%+8.1%-33.3%+7.1%+13.0%
Depreciation0.020.020.020.020.020.020.020.02
Interest0.000.010.000.020.010.010.010.00
Profit before tax0.85(1.29)0.950.660.32(0.12)0.210.36
Tax0.00(0.73)0.240.170.08(0.03)0.050.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue56.8069.6362.9462.6053.3849.0440.2248.36
Revenue growth (YoY)+6.4%+42.0%+56.5%+29.5%+6.5%+5.8%-21.1%+13.5%
Other income0.151.990.970.630.180.430.190.95
EBITDA4.304.665.718.087.446.634.287.24
EBITDA margin+7.6%+6.7%+9.1%+12.9%+13.9%+13.5%+10.6%+15.0%
Depreciation2.222.041.962.101.941.831.791.94
Interest1.641.611.471.401.221.281.231.38
Profit before tax0.593.003.255.214.463.951.454.87
Tax0.170.810.541.581.181.030.241.45
Net profit0.422.192.713.633.282.921.213.42
EPS (₹)0.371.902.373.152.852.551.062.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24918818916816390.0695.31
Revenue growth+38.3%-2.5%+14.2%+3.3%+74.7%-9.9%-9.8%
Other income3.781.680.820.770.330.210.66
Total expenses22316116514514080.1288.88
Employee cost0.0024.4323.7220.0517.4313.6814.08
EBITDA25.8826.7723.5522.9923.039.946.43
EBITDA margin+10.4%+14.3%+12.5%+13.7%+14.1%+11.0%+6.8%
Depreciation8.057.386.966.535.875.164.46
Interest5.715.395.354.955.235.084.60
Profit before tax15.9015.6812.0612.2812.26(0.09)(1.97)
Tax4.104.142.423.654.010.280.95
Net profit12.8011.719.608.618.23(0.38)(2.92)
Net profit margin+5.2%+6.2%+5.1%+5.1%+5.1%-0.4%-3.1%
EPS (₹)10.2710.038.377.508.40(0.43)(3.43)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.4911.4911.4911.499.818.508.50
Reserves & surplus83.6571.6160.0950.6736.5524.0424.29
Shareholders' funds (net worth)95.1483.1071.5862.1648.1832.5432.79
Minority interest0.160.140.120.110.090.080.07
Secured loans45.5828.5238.8522.7227.4821.5429.65
Unsecured loans37.2141.0141.7932.0041.6037.3621.58
Total debt82.7969.5380.6454.7269.0858.9051.23
Total liabilities17915315311711891.7884.37
Assets
Gross block16112912710897.2579.4072.73
Net block11588.2689.4876.8071.9559.6757.68
Capital work in progress11.2929.4420.612.333.344.912.91
Investments0.160.160.160.160.220.220.22
Inventories36.2225.7729.9321.6919.9310.7911.15
Sundry debtors37.8130.7632.5627.8938.0816.7123.08
Cash & bank balances2.262.681.882.785.781.271.30
Loans & advances14.395.568.944.967.2410.4710.08
Total current assets90.6864.7773.3157.3271.0339.2445.61
Total current liabilities42.4831.0532.6223.6632.4712.6121.10
Net working capital48.2033.7240.6933.6638.5626.6324.51
Total assets17915315311711891.7884.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.550.461.284.360.180.39(0.05)
Net cash from operating activities8.0032.3015.8820.918.556.318.75
Net cash from investing activities(16.39)(16.39)(31.52)(9.92)(16.50)(6.56)(13.33)
Net cash from financing activities8.18(15.82)14.82(14.07)12.130.055.03
Net change in cash(0.21)0.09(0.82)(3.08)4.18(0.21)0.44
Closing cash2.262.681.882.785.781.271.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-12.4%
EBITDA growth-3.3%+13.7%+2.4%-0.2%+131.7%+54.6%-37.1%
PBT growth+1.4%+30.0%-1.8%+0.2%+9998.0%+95.4%-
Net income growth+9.3%+22.0%+11.5%+4.6%+9998.0%+87.0%-
Revenue CAGR (3Y)+14.0%+4.8%+28.0%+20.7%+14.4%-5.1%+0.2%
EBITDA CAGR (3Y)+4.0%+5.1%+33.3%+52.9%+31.1%+0.2%-21.0%
Profitability & leverage
Net income margin+4.8%+6.2%+5.1%+5.2%+5.1%-0.4%-3.1%
Return on capital employed-+13.8%+12.9%+14.7%+16.7%+5.7%+3.2%
Return on net worth-+14.9%+14.4%+15.6%+20.5%-1.1%-8.5%
Debt / equity-0.971.011.121.591.691.36
Long-term debt / equity-0.360.340.330.470.570.53
Interest cover32.0227.8032.2530.0730.48106.28233.50
Efficiency & per share
Fixed asset turnover-1.471.611.631.851.181.42
Inventory turnover-6.747.318.0510.618.219.72
Debtors turnover-5.936.245.085.954.534.51
EPS (₹)10.2710.038.377.508.40(0.43)(3.43)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0072.3562.3254.1147.2438.2638.56
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2.570.252.711.701.970.840.991.54
Revenue growth (YoY)+30.5%-70.2%+173.7%+10.4%-46.2%-50.9%-64.3%-15.9%
Other income0.211.760.220.200.190.190.170.18
Total expenses1.913.271.961.201.811.120.921.34
EBITDA0.66(3.02)0.750.500.16(0.28)0.070.20
EBITDA margin+25.7%-1208.0%+27.7%+29.4%+8.1%-33.3%+7.1%+13.0%
Depreciation0.020.020.020.020.020.020.020.02
Interest0.000.010.000.020.010.010.010.00
Profit before tax0.85(1.29)0.950.660.32(0.12)0.210.36
Tax0.00(0.73)0.240.170.08(0.03)0.050.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6.637.027.447.477.152.377.68
Revenue growth+42.7%+8.0%-9.5%+2.3%+105.0%-60.5%+11.6%
Other income2.370.710.540.370.160.070.42
Total expenses8.255.785.355.915.782.827.13
Employee cost0.000.900.740.550.520.450.51
EBITDA(1.62)1.242.091.561.37(0.45)0.55
EBITDA margin-24.4%+17.7%+28.1%+20.9%+19.2%-19.0%+7.2%
Depreciation0.060.060.060.070.040.040.04
Interest0.030.020.140.250.710.831.38
Profit before tax0.661.872.431.610.78(1.25)(0.45)
Tax(0.24)0.460.620.420.24(0.12)1.53
Net profit0.931.411.811.190.54(1.13)(1.99)
Net profit margin+14.0%+20.1%+24.3%+15.9%+7.6%-47.7%-25.9%
EPS (₹)0.771.211.591.050.55(1.33)(2.36)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.4911.4911.4911.499.818.508.50
Reserves & surplus11.9311.069.677.871.12(3.79)(2.68)
Shareholders' funds (net worth)23.4222.5521.1619.3612.754.715.82
Secured loans0.000.000.001.071.892.632.77
Unsecured loans0.000.000.000.007.318.788.29
Total debt0.000.000.001.079.2011.4111.06
Total liabilities23.4522.5721.1820.4421.9516.1416.90
Assets
Gross block1.081.051.050.920.870.870.87
Net block0.390.430.490.430.440.480.53
Capital work in progress0.000.000.000.000.000.000.00
Investments10.0310.0310.0310.0310.0710.0710.07
Inventories0.800.780.900.580.790.580.15
Sundry debtors0.420.850.591.081.860.432.06
Cash & bank balances1.101.280.461.284.350.110.12
Loans & advances9.517.796.083.561.164.564.60
Total current assets11.8310.708.036.508.165.686.93
Total current liabilities1.001.741.070.931.581.501.75
Net working capital10.838.966.965.576.584.185.18
Total assets23.4522.5721.1820.4421.9516.1416.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.500.441.274.330.100.11(0.53)
Net cash from operating activities(0.72)0.280.08(0.28)(0.36)0.472.20
Net cash from investing activities0.57(0.19)0.300.140.000.00(0.01)
Net cash from financing activities(0.03)(0.02)(1.21)(2.92)4.59(0.48)(1.55)
Net change in cash(0.18)0.06(0.83)(3.07)4.23(0.01)0.64
Closing cash1.101.280.461.284.350.110.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%+18.3%
EBITDA growth--40.7%+34.0%+13.9%+9998.0%-+450.0%
PBT growth-64.7%-23.1%+50.9%+106.4%+9998.0%-177.8%+13.5%
Net income growth-34.0%-22.1%+52.1%+120.4%+9998.0%+43.2%-136.9%
Revenue CAGR (3Y)-3.9%-0.6%+46.4%-0.9%+3.3%-25.8%+13.3%
EBITDA CAGR (3Y)--3.3%-+41.6%+139.3%-26.0%-4.9%
Profitability & leverage
Net income margin+13.6%+20.1%+24.3%+15.9%+7.6%-47.7%-25.8%
Return on capital employed-+6.7%+9.1%+6.2%+6.2%0.0%0.0%
Return on net worth-+5.0%+6.5%+4.8%+4.0%0.0%0.0%
Debt / equity-0.000.030.321.182.131.63
Long-term debt / equity-0.000.000.040.170.440.42
Interest cover-1.791.696.9016.7853.38-169.39270.59
Efficiency & per share
Fixed asset turnover-6.697.558.358.222.728.83
Inventory turnover-8.3610.0510.9110.446.4926.95
Debtors turnover-9.758.915.086.241.903.37
EPS (₹)0.771.211.591.050.55(1.33)(2.36)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0019.6318.4216.8511.145.546.85
Want more history and ratios?
You're viewing the latest exchange-filed financials for Parnax Lab Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Parnax Lab Limited

Shareholding for the quarter ended Sep 2026: promoters hold 72.30%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.70%.

Promoters: 72.30%Retail & Others: 27.70%
Sep 2026
QUARTER
72.30% Promoters
27.70% Retail & Others
Promoter holding - history
Now 72.30% · Sep 2026High 72.30% · Dec 2025Low 72.30% · Dec 2025
71%71.8%72.5%73.3%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 72.30%Mar 2026: 72.30%Jun 2026: 72.30%Sep 2026: 72.30%72.30%72.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.30%72.30%72.30%72.30%
Public27.70%27.70%27.70%27.70%

Group Structure of Parnax Lab Limited

Parnax Lab has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key Subsidiaries
Company NameCINShares Held
Naxpar Pharma Private LimitedU52310MH2004PTC144449-

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Parnax Lab

Open charges
₹24.2 Cr
Satisfied charges
₹4.66 Cr
Breakdown by lending institutions
State Bank of India₹24.20 Cr
Latest charge details
DateLenderAmountStatus
07 Sep 2002State Bank of India₹10.39 CrOpen
30 Mar 2000State Bank of India₹2.72 CrOpen
30 Mar 2000State Bank of India₹10.39 CrOpen
04 May 1995State Bank of India₹26 LakhOpen
04 May 1995State Bank of India₹26 LakhOpen

Total charge records: 9 View all charges

Employees and EPFO Compliance at Parnax Lab

Employment history and EPFO contributions of people linked to Parnax Lab.

Premium access

Employee and EPFO history for Parnax Lab Limited

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Parnax Lab

Parnax Lab has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AAACK1457E1ZTMaharashtraActive01 Jul 2017
26AAACK1457E2ZUDadra and Nagar Haveli and Daman and DiuActive24 Nov 2017
Premium access

GST registrations and filing compliance for Parnax Lab Limited

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Parnax Lab

Premium access

Credit ratings, litigation, and regulatory alerts for Parnax Lab Limited

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Parnax Lab

Premium access

MSME payment history for Parnax Lab Limited

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Parnax Lab

Premium access

Corporate group structure for Parnax Lab Limited

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Parnax Lab

Premium access

MCA filings and documents for Parnax Lab Limited

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Parnax Lab

Activity
29 Sep 2025
Parnax Lab Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Parnax Lab Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
10 Feb 2025
Vijaykumar Shivaji Ayare was appointed as a Director on 10 Feb 2025 & has been associated with this company since 1 year 7 months.
Directors
03 Aug 2024
Mihir Prakash Shah was appointed as a Ceo on 03 Aug 2024 & has been associated with this company since 2 years 2 months.
Directors
03 Aug 2024
Binoy Baiju Shah was appointed as a Cfo on 03 Aug 2024 & has been associated with this company since 2 years 2 months.
Directors
05 Jul 2024
Mihir Prakash Shah was appointed as a Managing Director on 05 Jul 2024 & has been associated with this company since 2 years 3 months.

Recent News on Parnax Lab

Frequently Asked Questions about Parnax Lab Limited

Parnax Lab is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 August 1982 (44+ years old) and is registered under CIN L36912MH1982PLC027925. Listed on BSE: 506128.

Parnax Lab reported revenue of ₹248.54 Cr for FY 2025-26 (up 32.39% YoY) based on consolidated financials.

Parnax Lab has 6 current directors:

The GSTIN of Parnax Lab is 27AAACK1457E1ZT, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 26AAACK1457E2ZU (Dadra and Nagar Haveli and Daman and Diu).

The CIN (Corporate Identification Number) of Parnax Lab is L36912MH1982PLC027925. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Parnax Lab is listed on BSE with code 506128.

Parnax Lab was incorporated on 03 August 1982, making it 44+ years old. It is registered with the Registrar of Companies, Mumbai.

Parnax Lab can be reached through the website naxparlab.com. Its registered office is in Mumbai, Maharashtra, India.

The registered office of Parnax Lab is at Gala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available